港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

維立志博-B

63.100

-1.900-2.92%

成交量：61.14萬

成交額：3,877.53萬

市值：125.57億

市盈率：-31.42

高：64.550

開：62.950

低：62.550

收：65.000

52周最高：83.600

52周最低：44.720

股本：1.99億

香港流通股本：1.53億

量比：1.08

換手率：0.40%

股息：- -

股息率：- -

每股收益(LYR):-2.008

淨資產收益率：--

總資產收益率：--

市淨率：105.16

市盈率(LYR):-31.42

市銷率: - -

資料載入中...

總覽公司新聞資訊公告

維立志博－Ｂ(09887)股價上升5.087%，現價港幣$66.1

阿斯达克财经

維立志博-B盤中升逾8% 正式進入港股通股票名單

維立志博-B獲納入恒生綜合指數成份股及獲調入港股通股票名單

維立志博-B(09887)獲納入恒生綜合指數成份股及獲調入港股通股票名單

維立志博-B(09887)：維利信™於一線食管鱗狀細胞癌II期試驗的首例患者入組

每日沽空追蹤 | 維立志博-B 03月03日沽空量成交2.08萬股，沽空比例為3.95%

維立志博-B盤中異動下午盤股價大跌5.30%報56.300港元

維立志博生物科技（09887）2026年2月月報：股本維持不變

每日沽空追蹤 | 維立志博-B 02月27日沽空量成交1.31萬股，沽空比例為6.77%

瞄準 PD-1 未竟需求，雙抗/TCE/ADC 三箭齊發引領腫瘤免疫新升級｜專訪維立志博創始人康小強博士

每日沽空追蹤 | 維立志博-B 02月26日沽空量成交2.38萬股，沽空比例為9.35%

維立志博-B02月26日遭主力拋售90.9萬元

每日沽空追蹤 | 維立志博-B 02月23日沽空量成交2.81萬股，沽空比例為4.35%

維立志博-B午後上漲6% 公司下月有望成為港股通標的

每日沽空追蹤 | 維立志博-B 02月20日沽空量成交4700股，沽空比例為1.83%

IO2.0爭奪戰打響，下一代腫瘤「藥王」花落誰家？

【券商聚焦】西部證券首予維立志博-B「買入」評級指公司核心產品臨床數據亮眼

維立志博－Ｂ(09887)股價上升5.053%，現價港幣$64.45

阿斯达克财经

維立志博獲納入恒生綜合指數，即將成為港股通可投資標的

维立志博生物科技

維立志博-B02月13日主力淨流入605.1萬元散户資金拋售

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/09887/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"09887","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","market":"HK","secType":"STK","nameCN":"維立志博-B","latestPrice":63.1,"timestamp":1774253289010,"preClose":65,"halted":0,"volume":611400,"delay":0,"changeRate":-0.02923076923076921,"floatShares":153000000,"shares":199000000,"eps":-2.008042,"marketStatus":"已收盤","change":-1.9,"latestTime":"03-23 16:08:09","open":62.95,"high":64.55,"low":62.55,"amount":38775348,"amplitude":0.030769,"askPrice":63.6,"askSize":500,"bidPrice":63.1,"bidSize":1900,"shortable":3,"etf":0,"ttmEps":-1.583,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1774315800000},"marketStatusCode":5,"adr":0,"listingDate":1753372800000,"exchange":"SEHK","adjPreClose":65,"openAndCloseTimeList":[[1774229400000,1774238400000],[1774242000000,1774252800000]],"volumeRatio":1.083535,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","floatShares":153000000,"roa":"--","roe":"--","lyrEps":-2.008042,"volumeRatio":1.083535,"shares":199000000,"dividePrice":0,"high":64.55,"amplitude":0.030769,"preClose":65,"low":62.55,"week52Low":44.72,"pbRate":"105.16","week52High":83.6,"institutionHeld":0,"latestPrice":63.1,"committee":0.583333,"eps":-2.008042,"divideRate":0,"volume":611400,"delay":0,"ttmEps":-1.583,"open":62.95,"prevYearClose":51,"prevWeekClose":65,"prevMonthClose":62.7,"prevQuarterClose":51,"fiveDayClose":63.65,"twentyDayClose":68.75,"sixtyDayClose":50.2,"earningDate":1774540800000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09887\",params:#limit:5,,,undefined,":[{"date":"2026-03-27","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774575000000,"name":null,"time":"","dateTimestamp":1774540800000,"actualEps":null},{"date":"2025-08-29","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756431000000,"name":null,"time":"","dateTimestamp":1756396800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09887\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09887\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.5,"hold":0.25,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":4,"updateTime":1762358400000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09887\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09887","date":"2026-03-20","current":-39.861023,"percent":0.416149,"low":-50.052922,"twenty":-41.914066,"median":-38.162788,"eighty":-33.431073,"high":-30.202688,"avg":-38.150019,"sd":4.382014,"marketCap":12927967000},"quantilePoints":[{"date":"2025-07-25","current":-39.760016,"twenty":-39.760016,"median":-39.760016,"eighty":-39.760016,"marketCap":12652000240},{"date":"2025-08-01","current":-42.800562,"twenty":-46.836196,"median":-44.399434,"eighty":-42.800562,"marketCap":13535375000},{"date":"2025-08-08","current":-41.931377,"twenty":-45.734702,"median":-43.894587,"eighty":-42.800562,"marketCap":13293671875},{"date":"2025-08-15","current":-42.360797,"twenty":-44.683717,"median":-42.975881,"eighty":-41.70245,"marketCap":13409689375},{"date":"2025-08-22","current":-41.268557,"twenty":-45.0887,"median":-43.050098,"eighty":-41.70245,"marketCap":13022964375},{"date":"2025-08-29","current":-41.462871,"twenty":-44.683717,"median":-42.745269,"eighty":-41.268557,"marketCap":13146747980},{"date":"2025-09-05","current":-41.718992,"twenty":-44.115151,"median":-41.93996,"eighty":-40.603026,"marketCap":13087080440},{"date":"2025-09-12","current":-41.612383,"twenty":-43.894587,"median":-41.766832,"eighty":-40.253447,"marketCap":13077135850},{"date":"2025-09-19","current":-40.406926,"twenty":-43.894587,"median":-41.814673,"eighty":-40.270938,"marketCap":12689296840},{"date":"2025-09-26","current":-39.940552,"twenty":-43.592616,"median":-41.710721,"eighty":-39.940552,"marketCap":12510294220},{"date":"2025-10-03","current":-46.021818,"twenty":-44.124681,"median":-41.829747,"eighty":-40.190868,"marketCap":14449489270},{"date":"2025-10-10","current":-44.344385,"twenty":-44.480118,"median":-41.935668,"eighty":-40.263942,"marketCap":13902536820},{"date":"2025-10-17","current":-41.267963,"twenty":-44.480118,"median":-42.061577,"eighty":-40.352531,"marketCap":12927967000},{"date":"2025-10-24","current":-37.571928,"twenty":-44.331016,"median":-41.888099,"eighty":-40.263942,"marketCap":11774394560},{"date":"2025-10-31","current":-34.030535,"twenty":-44.258383,"median":-41.766832,"eighty":-39.846145,"marketCap":10680489660},{"date":"2025-11-07","current":-37.063837,"twenty":-44.143742,"median":-41.612383,"eighty":-39.421071,"marketCap":11625225710},{"date":"2025-11-14","current":-37.306884,"twenty":-44.026925,"median":-41.504614,"eighty":-38.171485,"marketCap":11734616200},{"date":"2025-11-21","current":-32.263354,"twenty":-43.773799,"median":-41.293984,"eighty":-37.626872,"marketCap":10143481800},{"date":"2025-11-28","current":-33.407237,"twenty":-43.416049,"median":-41.25873,"eighty":-37.278832,"marketCap":10541265400},{"date":"2025-12-05","current":-32.531883,"twenty":-43.110759,"median":-40.854935,"eighty":-36.232015,"marketCap":10282706060},{"date":"2025-12-12","current":-33.445348,"twenty":-43.033782,"median":-40.504976,"eighty":-34.804627,"marketCap":10590988350},{"date":"2025-12-19","current":-31.455565,"twenty":-42.962519,"median":-40.253447,"eighty":-33.697999,"marketCap":9984368360},{"date":"2025-12-24","current":-31.920084,"twenty":-42.892338,"median":-39.907071,"eighty":-33.445348,"marketCap":10163370980},{"date":"2026-01-02","current":-31.421623,"twenty":-42.818917,"median":-39.811672,"eighty":-33.24713,"marketCap":10044035900},{"date":"2026-01-09","current":-34.757237,"twenty":-42.712093,"median":-39.628079,"eighty":-33.303022,"marketCap":11137940800},{"date":"2026-01-16","current":-34.953981,"twenty":-42.570843,"median":-39.220132,"eighty":-33.387129,"marketCap":11237386700},{"date":"2026-01-23","current":-34.708884,"twenty":-42.534258,"median":-38.04671,"eighty":-33.234922,"marketCap":11147885390},{"date":"2026-01-30","current":-41.208386,"twenty":-42.402729,"median":-37.93488,"eighty":-33.285275,"marketCap":13295916830},{"date":"2026-02-06","current":-38.552413,"twenty":-42.362692,"median":-38.04671,"eighty":-33.303022,"marketCap":12470515860},{"date":"2026-02-13","current":-37.506904,"twenty":-42.335079,"median":-38.011119,"eighty":-33.387129,"marketCap":12202011930},{"date":"2026-02-20","current":-39.795685,"twenty":-42.275235,"median":-38.202679,"eighty":-33.413439,"marketCap":12927967000},{"date":"2026-02-27","current":-37.9711,"twenty":-42.061223,"median":-38.358648,"eighty":-33.438876,"marketCap":12470515860},{"date":"2026-03-06","current":-32.876582,"twenty":-42.035836,"median":-37.973315,"eighty":-33.326804,"marketCap":10710323430},{"date":"2026-03-13","current":-37.800338,"twenty":-41.938243,"median":-37.9711,"eighty":-33.411645,"marketCap":12371069960},{"date":"2026-03-20","current":-39.652105,"twenty":-41.914066,"median":-38.162788,"eighty":-33.431073,"marketCap":12927967000}],"updateTime":1774278961114},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09887\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2620319287","title":"維立志博－Ｂ(09887)股價上升5.087%，現價港幣$66.1","url":"https://stock-news.laohu8.com/highlight/detail?id=2620319287","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620319287?lang=zh_tw&edition=fundamental","pubTime":"2026-03-18 14:34","pubTimestamp":1773815640,"startTime":"0","endTime":"0","summary":"[上升股]维立志博－Ｂ(09887) 股价在下午02:34比前收市价上升5.087%，现股价为港币$66.1。至目前为止，今日最高价为$66.1，而最低价为$61.95。总成交量为47.642万股，总成交金额为港币$3.072千万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190515141041255_s.png","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190515141041255_s.png"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2603182380/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2603182380/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","HK0000500386.USD","09887","HK0000252160.HKD","HK0000252152.HKD"],"gpt_icon":0},{"id":"2618761585","title":"維立志博-B盤中升逾8% 正式進入港股通股票名單","url":"https://stock-news.laohu8.com/highlight/detail?id=2618761585","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618761585?lang=zh_tw&edition=fundamental","pubTime":"2026-03-09 10:35","pubTimestamp":1773023700,"startTime":"0","endTime":"0","summary":"　　维立志博-B盘初涨超8%，截至发稿，股价上涨6.04%，现报57.10港元，成交额1.15亿港元。　　维立志博公布，自2026年3月9日起，公司股份将获恒生指数有限公司纳入恒生综合指数成份股及获调入港股通标的名单。　　此外，3月6日，维立志博宣布，公司自主研发的PD-L1/4-1BB双特异性抗体维利信联合用药一线治疗局部晚期或转移性食管鳞癌的Ⅱ期临床研究顺利完成首例患者入组。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-03-09/doc-inhqizzu7097010.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","09887","HK0000252160.HKD","VXUS","HK0000252152.HKD","HK0000500386.USD","BK4585","VT","BK1161"],"gpt_icon":0},{"id":"2617666837","title":"維立志博-B獲納入恒生綜合指數成份股及獲調入港股通股票名單","url":"https://stock-news.laohu8.com/highlight/detail?id=2617666837","media":"新浪港股","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617666837?lang=zh_tw&edition=fundamental","pubTime":"2026-03-08 10:08","pubTimestamp":1772935680,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　维立志博-B（09887）发布公告，自2026年3月9日起，公司股份将获恒生指数有限公司纳入恒生综合指数成份股及获调入港股通标的名单。\n　　股份获纳入恒生综合指数及港股通标的证券是资本市场对公司表现及价值的高度认可，并允许中国内地合资格投资者透过沪港通及深港通机制直接投资于香港联合交易所有限公司上市的股份。预期纳入将进一步扩大公司的投资者基础，提升股份的交易流动性，并进一步优化股东结构。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-03-08/doc-inhqfsuq1032680.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["VT","HK0000252160.HKD","VXUS","HK0000252152.HKD","BK1161","09887","BK4585","BK4588","HSCI","HK0000500386.USD"],"gpt_icon":0},{"id":"2617857206","title":"維立志博-B(09887)獲納入恒生綜合指數成份股及獲調入港股通股票名單","url":"https://stock-news.laohu8.com/highlight/detail?id=2617857206","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617857206?lang=zh_tw&edition=fundamental","pubTime":"2026-03-06 17:15","pubTimestamp":1772788549,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B(09887)发布公告，自2026年3月9日起，公司股份将获恒生指数有限公司纳入恒生综合指数成份股及获调入港股通标的名单。股份获纳入恒生综合指数及港股通标的证券是资本市场对公司表现及价值的高度认可，并允许中国内地合资格投资者透过沪港通及深港通机制直接投资于香港联合交易所有限公司上市的股份。预期纳入将进一步扩大公司的投资者基础，提升股份的交易流动性，并进一步优化股东结构。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411007.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000252152.HKD","HK0000252160.HKD","BK1161","HSCI","VXUS","BK4585","BK4588","VT","HK0000500386.USD","09887"],"gpt_icon":0},{"id":"2617683670","title":"維立志博-B(09887)：維利信™於一線食管鱗狀細胞癌II期試驗的首例患者入組","url":"https://stock-news.laohu8.com/highlight/detail?id=2617683670","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617683670?lang=zh_tw&edition=fundamental","pubTime":"2026-03-06 16:33","pubTimestamp":1772786017,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B(09887)发布公告，评价维利信™(PD-L1/4-1BB双特异性抗体奥帕替苏米单抗，LBL-024)用于治疗一线食管鳞状细胞癌的II期临床研究首例患者已成功入组。本次开展的开放标签、多中心Ⅱ期临床研究由北京大学肿瘤医院沈琳院长牵头，正在全国多家医院同步推进。该试验旨在评价奥帕替苏米单抗用于治疗一线食管鳞状细胞癌患者的有效性和安全性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1410955.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09887","BK1161","HK0000252160.HKD","HK0000500386.USD","HK0000252152.HKD"],"gpt_icon":0},{"id":"2616320220","title":"每日沽空追蹤 | 維立志博-B 03月03日沽空量成交2.08萬股，沽空比例為3.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616320220","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616320220?lang=zh_tw&edition=fundamental","pubTime":"2026-03-03 16:30","pubTimestamp":1772526644,"startTime":"0","endTime":"0","summary":"维立志博-B北京时间03月03日，跌8.16%，卖空量成交2.08万股，较上一交易日减少43.48%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303163623a445cefd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303163623a445cefd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000500386.USD","09887","BK1161","HK0000252160.HKD","HK0000252152.HKD"],"gpt_icon":0},{"id":"2616788320","title":"維立志博-B盤中異動 下午盤股價大跌5.30%報56.300港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2616788320","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616788320?lang=zh_tw&edition=fundamental","pubTime":"2026-03-03 14:01","pubTimestamp":1772517678,"startTime":"0","endTime":"0","summary":"2026年03月03日下午盘14时01分，维立志博-B股票出现波动，股价大幅跳水5.30%。截至发稿，该股报56.300港元/股，成交量21.77万股，换手率0.14%，振幅8.24%。资金方面，该股资金流入316.098万港元，流出715.384万港元。维立志博-B股票所在的生物技术行业中，整体跌幅为3.55%。维立志博-B公司简介：我们是一家临床阶段生物科技公司,致力于创新疗法的发现、开发及商业化,以满足中国及全球在肿瘤、自身免疫性疾病及其他重大疾病方面未获满足的医疗需求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603031401189542bbc0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603031401189542bbc0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000252160.HKD","HK0000252152.HKD","BK1161","09887","HK0000500386.USD"],"gpt_icon":0},{"id":"1100714503","title":"維立志博生物科技（09887）2026年2月月報：股本維持不變","url":"https://stock-news.laohu8.com/highlight/detail?id=1100714503","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100714503?lang=zh_tw&edition=fundamental","pubTime":"2026-03-03 12:25","pubTimestamp":1772511938,"startTime":"0","endTime":"0","summary":"维立志博生物科技有限公司（09887）于2026年3月3日发布2026年2月股份变动月报表。公告显示，截至2026年2月28日，公司的注册股本总额为人民币198,891,800元，与上月持平，维持不变。\n公司目前拥有两类股份：其中H股已发行股份153,278,691股，未上市普通股则为45,613,109股。报告期内并未出现新增发行、购回、注销或库藏股变动，公司股本结构保持稳定。\n此外，公告确认公司已满足香港联合交易所有限公司相关上市规则的公众持股量要求。根据公告内容，公司承诺遵守所有适用的上市规则、法律及监管规定，所有权文件及履行程序均已合规完成。\n本次公告由联席公司秘书左洪刚签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"gpt_icon":0},{"id":"2614686513","title":"每日沽空追蹤 | 維立志博-B 02月27日沽空量成交1.31萬股，沽空比例為6.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614686513","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614686513?lang=zh_tw&edition=fundamental","pubTime":"2026-02-27 16:30","pubTimestamp":1772181043,"startTime":"0","endTime":"0","summary":"维立志博-B北京时间02月27日，涨1.54%，卖空量成交1.31万股，较上一交易日减少69.89%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227163618a4367ac4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227163618a4367ac4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000252160.HKD","HK0000500386.USD","09887","BK1161","HK0000252152.HKD"],"gpt_icon":0},{"id":"2614882016","title":"瞄準 PD-1 未竟需求，雙抗/TCE/ADC 三箭齊發引領腫瘤免疫新升級｜專訪維立志博創始人康小強博士","url":"https://stock-news.laohu8.com/highlight/detail?id=2614882016","media":"医麦客","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614882016?lang=zh_tw&edition=fundamental","pubTime":"2026-02-27 07:21","pubTimestamp":1772148065,"startTime":"0","endTime":"0","summary":"超过 30 年创新药研发经验，其中 17 年以上抗体新药研发经验，领导多个抗癌抗体新药研发。临床数据显示，PD-1 对约 80% 的患者无效或最终耐药。根据目前已有的数据，LBL-024 在非小细胞肺癌、小细胞肺癌和肺外神经内分泌癌三个适应症的二期或注册性临床试验中展示出全球首创和同类最优潜力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022707244295422735&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022707244295422735&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000252160.HKD","HK0000500386.USD","09887","HK0000252152.HKD","BK1161"],"gpt_icon":0},{"id":"2614073006","title":"每日沽空追蹤 | 維立志博-B 02月26日沽空量成交2.38萬股，沽空比例為9.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614073006","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614073006?lang=zh_tw&edition=fundamental","pubTime":"2026-02-26 16:30","pubTimestamp":1772094642,"startTime":"0","endTime":"0","summary":"维立志博-B北京时间02月26日，跌3.21%，卖空量成交2.38万股，较上一交易日增加16.1%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226163623a7219d34&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226163623a7219d34&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","HK0000252160.HKD","HK0000252152.HKD","09887","HK0000500386.USD"],"gpt_icon":0},{"id":"2614073000","title":"維立志博-B02月26日遭主力拋售90.9萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614073000","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614073000?lang=zh_tw&edition=fundamental","pubTime":"2026-02-26 16:15","pubTimestamp":1772093753,"startTime":"0","endTime":"0","summary":"02月26日, 维立志博-B股价跌3.21%，报收61.75元，成交金额1588.8万元，换手率0.17%，振幅4.94%，量比0.59。维立志博-B今日主力资金净流出90.9万元，连续3日净流出，上一交易日主力净流出63.4万元。该股近5个交易日下跌5.73%，主力资金累计净流入253.0万元；近20日主力资金累计净流入5550.7万元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226162015a7218a00&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226162015a7218a00&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887","HK0000252152.HKD","HK0000252160.HKD","BK1161","HK0000500386.USD"],"gpt_icon":0},{"id":"2613262766","title":"每日沽空追蹤 | 維立志博-B 02月23日沽空量成交2.81萬股，沽空比例為4.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613262766","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613262766?lang=zh_tw&edition=fundamental","pubTime":"2026-02-23 16:30","pubTimestamp":1771835443,"startTime":"0","endTime":"0","summary":"维立志博-B北京时间02月23日，涨5.77%，卖空量成交2.81万股，较上一交易日增加301.43%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223163550a4be7eea&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223163550a4be7eea&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","HK0000500386.USD","09887","HK0000252160.HKD","HK0000252152.HKD"],"gpt_icon":0},{"id":"2613967204","title":"維立志博-B午後上漲6% 公司下月有望成為港股通標的","url":"https://stock-news.laohu8.com/highlight/detail?id=2613967204","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613967204?lang=zh_tw&edition=fundamental","pubTime":"2026-02-23 14:51","pubTimestamp":1771829460,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　维立志博-B（09887）午后股价上涨6%，现报68.90港元，成交额3078.41万港元。\n　　恒生指数公司此前宣布季度检讨结果，维立志博获纳入恒生综合指数，所有变动将于3月6日收市后实施并于3月9日起生效。中金发布研报指，维立志博3月有可能被调入港股通。西部证券则表示，考虑到公司2026年临床数据催化较多，2027年有望进入商业化拐点。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-02-23/doc-inhnusxe6044217.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4585","VT","BK4588","09887","HK0000252152.HKD","HK0000252160.HKD","BK1161","HK0000500386.USD","VXUS"],"gpt_icon":0},{"id":"2612626178","title":"每日沽空追蹤 | 維立志博-B 02月20日沽空量成交4700股，沽空比例為1.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2612626178","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612626178?lang=zh_tw&edition=fundamental","pubTime":"2026-02-20 16:30","pubTimestamp":1771576240,"startTime":"0","endTime":"0","summary":"维立志博-B北京时间02月20日，跌0.76%，卖空量成交4700股，较上一交易日减少83.79%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260220163555a70cd18e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260220163555a70cd18e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000252152.HKD","BK1161","09887","HK0000252160.HKD","HK0000500386.USD"],"gpt_icon":0},{"id":"2612252506","title":"IO2.0爭奪戰打響，下一代腫瘤「藥王」花落誰家？","url":"https://stock-news.laohu8.com/highlight/detail?id=2612252506","media":"药创新","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612252506?lang=zh_tw&edition=fundamental","pubTime":"2026-02-20 15:00","pubTimestamp":1771570819,"startTime":"0","endTime":"0","summary":"下一代肿瘤“药王”争夺战打响！撰文丨粽哥2025下一代肿瘤“药王”，极有可能诞生于PD-1+X领域。以K药为代表的PD-1单抗，开启了一代IO治疗时代，但却存在耐药和冷肿瘤缺乏应答的问题。临床上，T细胞耗竭现象是导致免疫检查点获得性耐药的关键机制。TIGIT是经典免疫逃逸靶点，在多种淋巴细胞上表达，被认为是“下一个PD-1”。不过，PD-1/TIGIT双抗或有望打破TIGIT“难以成药”的魔咒。TIGIT和PD-1表达之间存在很强的相关性，特别是在肺癌的肿瘤浸","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602201513389541818d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602201513389541818d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01530","LU0348767384.USD","LU0634319403.HKD","LU0540923850.HKD","LU0348825331.USD","02898","LU2476274308.USD","LU2476274720.SGD","BK1161","LU0348827113.USD","LU2488822045.USD","09995","LU1794554557.SGD","LU2778985437.USD","IE00B543WZ88.USD","09926","02616","LU0348735423.USD","LU0417516902.SGD","01801","02696","LU1720050803.USD","LU1961090484.USD","01877","09887","LU0348784397.USD","IE00B5MMRT66.SGD","01177","LU0348783233.USD","LU0417516571.SGD","LU2399975544.HKD","LU0348766576.USD","IE00BPRC5H50.USD","LU0561508036.HKD","BK1574","LU0417516738.SGD"],"gpt_icon":1},{"id":"2612204261","title":"【券商聚焦】西部證券首予維立志博-B「買入」評級 指公司核心產品臨床數據亮眼","url":"https://stock-news.laohu8.com/highlight/detail?id=2612204261","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612204261?lang=zh_tw&edition=fundamental","pubTime":"2026-02-20 10:04","pubTimestamp":1771553054,"startTime":"0","endTime":"0","summary":"金吾财讯|西部证券发布研报指，维立志博-B核心产品LBL-024在肺外神经内分泌癌临床数据优异，单药治疗3L+ EP-NEC ORR达33.3%，计划2026Q3递交BLA；LBL-034在复发难治多发性骨髓瘤I期ORR达82.5%。研报指出，LBL-024是全球首个进入注册临床的4-1BB靶向药物，已布局12个适应症，9项临床试验进行中。目标价未披露，首次覆盖给予\"买入\"评级。主要风险包括临床开发进度不及预期、商业化风险及核心人员流失。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260220102227a70bf099&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260220102227a70bf099&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887"],"gpt_icon":0},{"id":"2611724461","title":"維立志博－Ｂ(09887)股價上升5.053%，現價港幣$64.45","url":"https://stock-news.laohu8.com/highlight/detail?id=2611724461","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611724461?lang=zh_tw&edition=fundamental","pubTime":"2026-02-16 09:40","pubTimestamp":1771206000,"startTime":"0","endTime":"0","summary":"[上升股]维立志博－Ｂ(09887) 股价在上午09:40比前收市价上升5.053%，现股价为港币$64.45。至目前为止，今日最高价为$64.45，而最低价为$61.35。总成交量为5.24万股，总成交金额为港币$332.101万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152547499_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152547499_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR260216629/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR260216629/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["09887","HK0000500386.USD","HK0000252160.HKD","BK1161","HK0000252152.HKD"],"gpt_icon":0},{"id":"2611146423","title":"維立志博獲納入恒生綜合指數，即將成為港股通可投資標的","url":"https://stock-news.laohu8.com/highlight/detail?id=2611146423","media":"维立志博生物科技","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611146423?lang=zh_tw&edition=fundamental","pubTime":"2026-02-14 10:11","pubTimestamp":1771035084,"startTime":"0","endTime":"0","summary":"2026年2月14日，南京维立志博生物科技股份有限公司今日欣然宣布，根据恒生指数公司于2026年2月13日公布的截至2025年12月31日之恒生指数系列季度检讨结果，公司已获纳入恒生综合指数。获纳入恒生综合指数后，公司有望进一步成为港股通可投资标的，这将为公司引入更多来自中国内地的多元化投资者，进一步提升公司股票的交易流动性及估值水平。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021411292097a6296c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021411292097a6296c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","HK0000252160.HKD","HK0000252152.HKD","HSCI","HK0000500386.USD","09887"],"gpt_icon":0},{"id":"2611824169","title":"維立志博-B02月13日主力淨流入605.1萬元 散户資金拋售","url":"https://stock-news.laohu8.com/highlight/detail?id=2611824169","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611824169?lang=zh_tw&edition=fundamental","pubTime":"2026-02-13 16:15","pubTimestamp":1770970515,"startTime":"0","endTime":"0","summary":"02月13日, 维立志博-B股价涨0.90%，报收61.35元，成交金额2257.8万元，换手率0.24%，振幅4.93%，量比1.03。维立志博-B今日主力资金净流入605.1万元，上一交易日主力净流出174.0万元。该股近5个交易日下跌1.59%，主力资金累计净流入116.9万元，其中2个交易日为股价上涨时净流出；近20日主力资金累计净流入4687.6万元，其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213161544a6f6cfd3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213161544a6f6cfd3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","HK0000500386.USD","09887","HK0000252160.HKD","HK0000252152.HKD"],"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":1,"totalSize":158,"code":"91000000","status":"200"}]}}